Характер течения артериальной гипертонии при низкорениновом гиперальдостеронизме
https://doi.org/10.26442/2075082X.2019.4.190574
Аннотация
Список литературы
1. Funder J.W, Carey R.M, Mantero F et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889-916.
2. Чихладзе Н.М. Симптоматические (вторичные) артериальные гипертонии. Диагностика и лечение. Библиотека ФГБУ «НМИЦ кардиологии» Минздрава России. М.: МИА, 2018.
3. Conn J.W. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
4. Baer L, Sommers S.C, Krakoff L.R et al. Pseudoprimary aldosteronism: an entity distinct from true primary aldosteronism. Circ Res 1970; 27 (Suppl. 1): 203-20.
5. Pignatelli D, Falcao H, Coimara-Pixoto A, Cruz F. Unilateral adrenal hyperplasia. South Med J 1994; 87: 664-7.
6. Omura M, Sasano H, Fujiwara T et al. Unique Cases of Unilateral Hyperaldosteronemia Due to Multiple Adrenocortical Micronodules, Which Can Only be Detected by Selective Adrenal Venous Sampling. Metabolism 2002; 51 (3): 350-5.
7. Stowasser M, Gartside M.G, Gordon R.D. A PCR-based method of sсreening individuals of all ages, from neonates to the elderly, for familial hyperaldosteronism type I. Aust NZJ 1997; 27: 685-90.
8. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018; 9: 115-22.
9. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-18.
10. Ruilope L.M. Aldosterone, Hypertension, and cardiovascular disease. Hypertension 2008; 52: 207.
11. Knoz F.G, Burnett J.C, Kohan D.E et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Intern 1980; 17: 263-76.
12. Шхвацабая И.К., Чихладзе Н.М. Гиперальдостеронизм и артериальная гипертония. М.: Медицина, 1984.
13. Mosso L, Carvajal C, González A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-5.
14. Monticone S, Burrello J, Tizzani D et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-20.
15. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region. J Hum Hypertens 2003; 17: 349-52.
16. Самедова Х.Ф., Чихладзе Н.М., Блинова Е.В. и др. Оценка функционального состояния миокарда у больных артериальной гипертонией на фоне гиперальдостеронизма с использованием ортогональной электрокардиографии. Кардиоваскулярная терапия и профилактика. 2006; 5 (2): 15-9.
17. Cushman W.C, Ford C.E, Cutler J.A et al; for the ALLHAT Collaborative Research Group: Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.
18. Calhoun D.A. Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1 (5): 1039-45.
19. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371 (9628): 1921-6.
20. Чихладзе Н.М., Бронштейн М.Э., Казеев К.Н., Арабидзе Г.Г. Кризовое течение артериальной гипертонии у больных с первичным гиперальдостеронизмом. Кардиология. 1989; 11: 95-9.
21. Stowasser M, Bachmann A.W, Huggard P.R et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85 (6): 2160-6.
22. Mulatero P, Tizzani D, Viola A et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58 (5): 797-803.
23. Ito Y, Takeda R, Karashima S et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102.
24. Moradi S, Shafiepour M, Amirbaigloo A. A woman with normotensive primary hyperaldosteronism. Acta Medica Iranica 2016; 54 (2): 156-8.
25. Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-95.
26. Médeau V, Moreau F, Trinquart L et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol 2008; 69 (1): 20-8.
27. Vantyghem M-C, Ronci N, Provost F et al. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141: 279-85.
28. Nishimiya T, Kikuchi K, Oimatsu H et al. A case of normotensive primary aldosteronism - comparison with 13 previously experienced cases with hypertension. Endocrinol Jpn 1984; 31 (2): 159-64.
29. Rossi G.P. Does primary aldosteronism exist in normotensive and mildly hypertensive patients, and should we look for it? Hypertens Res 2011; 34: 43-6.
Рецензия
Для цитирования:
Чихладзе Н.М. Характер течения артериальной гипертонии при низкорениновом гиперальдостеронизме. Системные гипертензии. 2019;16(4):22-26. https://doi.org/10.26442/2075082X.2019.4.190574
For citation:
Chikhladze N.M. The nature of the course of arterial hypertension in low-renin hyperaldosteronism. Systemic Hypertension. 2019;16(4):22-26. (In Russ.) https://doi.org/10.26442/2075082X.2019.4.190574